Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1983]

Advances in multiple myeloma from EHA 2012

Prof Meletios Dimopoulos - Univeristy of Athens, Greece

Advances in multiple myeloma from EHA 2012 ( Prof Meletios Dimopoulos - Univeristy of Athens, Greece )

Advances in multiple myeloma from EHA 2012; bortezomib and beyond

Prof Heinz Ludwig - Wilhelminenspital, Center for Oncology and Hematology...

Advances in multiple myeloma from EHA 2012; bortezomib and beyond ( Prof Heinz Ludwig - Wilhelminenspital, Center for Oncology and Hematology, Vienna, Austria )

Dasatinib vs. imatinib first-line in CML; new study data

Prof Giuseppe Saglio - University of Turin, Italy

Dasatinib vs. imatinib first-line in CML; new study data ( Prof Giuseppe Saglio - University of Turin, Italy )

The evolving landscape in CML management

Dr Delphine Rea - Saint Louis Hospital, Paris

The evolving landscape in CML management ( Dr Delphine Rea - Saint Louis Hospital, Paris )

AZA in MDS, and managing the older MDS patient

Prof Valeria Santini – University of Florence, Italy

AZA in MDS, and managing the older MDS patient ( Prof Valeria Santini – University of Florence, Italy )

Lenalidomide in low-risk MDS del(5q)

Prof Aristoteles Giagounidis - St. John’s Hospital, Duisburg, Germany

Lenalidomide in low-risk MDS del(5q) ( Prof Aristoteles Giagounidis - St. John’s Hospital, Duisburg, Germany )

EHA 2012 advances in lymphoma; lenalidamide and beyond

Prof John Gribben - Barts & The London Trust Cancer Centre, UK; Prof Gilles...

EHA 2012 advances in lymphoma; lenalidamide and beyond ( Prof John Gribben - Barts & The London Trust Cancer Centre, UK; Prof Gilles Salles - Universite Claude Bernard, Lyon, France )

Identifying drug sensitivity and resistance in acute myeloid leukaemia

Dr Mark Frattini – Memorial Sloan-Kettering Cancer Center, New York, USA

Identifying drug sensitivity and resistance in acute myeloid leukaemia ( Dr Mark Frattini – Memorial Sloan-Kettering Cancer Center, New York, USA )

Addressing the problem of adherence to treatment

Giora Sharf – Israeli CML Patients Support Group

Addressing the problem of adherence to treatment ( Giora Sharf – Israeli CML Patients Support Group )

Patient and doctor communication and quality of life guidelines

Jan Geissler – CML Advocates Network

Patient and doctor communication and quality of life guidelines ( Jan Geissler – CML Advocates Network )

GFI is crucial for AML1-ETO induced acute myeloid leukemia

Dr Bert van der Reijden – Radboud University Nijmegen Medical Centre, Holland

GFI is crucial for AML1-ETO induced acute myeloid leukemia ( Dr Bert van der Reijden – Radboud University Nijmegen Medical Centre, Holland )

Signaling and targeting cellular pathways in leukaemia metabolism

Dr Jing Chen – Emory University School of Medicine, Atlanta, USA

Signaling and targeting cellular pathways in leukaemia metabolism ( Dr Jing Chen – Emory University School of Medicine, Atlanta, USA )

More from ecancer